TP63 and esophageal squamous cell carcinoma: Recently, large-scale genomic and epigenomic studies have revealed the genetic and epigenetic landscape of ESCC and identified recurring mutations or deletions in TP53, CDKN2A, and RB1, and frequent amplifications of SOX2, TP63, and FGFR1 [2], making them essential parts of the molecular repertoire defining the “squamous” subtype.